Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. College of Medicine /醫學院
  3. Institute of Medicine/醫學研究所
  4. Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel
 
  • Details
Options

Geriatric Nutritional Risk Index as a Prognostic Marker for Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel

Journal
Frontiers in Pharmacology
Journal Volume
11
ISSN
1663-9812
Date Issued
2021-01-25
Author(s)
Li-Wen Chang
Sheng-Chun Hung
Jian-Ri Li
Kun-Yuan Chiu
Cheng-Kuang Yang
Chuan-Shu Chen
Kevin Lu
Cheng-Che Chen
Shu-Chi Wang
Chia-Yen Lin
Chen-Li Cheng
Yen-Chuan Ou
Shun-Fa Yang  
Chiann-Yi Hsu
Szu-Hang Ho
Shian-Shiang Wang
DOI
10.3389/fphar.2020.601513
URI
https://scholars.csmu.edu.tw/handle/123456789/4127
Abstract
<jats:p><jats:bold>Purpose:</jats:bold> To investigate the prognostic efficacy of the Geriatric Nutritional Risk Index (GNRI) in patients with metastatic Castration–resistant Prostate Cancer (mCRPC) receiving docetaxel as the first line of treatment.</jats:p><jats:p><jats:bold>Methods:</jats:bold> We retrospectively reviewed patients with mCRPC and receiving first line docetaxel in Taichung Veterans General Hospital from 2006 to 2012. The GNRI was calculated using serum albumin and body mass index, with a poor nutritional status defined as GNRI &lt;92.0. Multivariate Cox-regression analysis was used to evaluate the risk of survival.</jats:p><jats:p><jats:bold>Results:</jats:bold> One-hundred seventy patients with mCRPC were included. One-hundred twenty-five patients were of normal nutritional status (GNRI ≥92) and 45 patients were of poor nutritional status (GNRI &lt;92). The cumulative docetaxel dosage was 600 (360–1,185) mg in the normal nutritional status group and 360 (127.5–660) mg in the poor nutritional status group (<jats:italic>p</jats:italic> &lt; 0.001). The median overall survival from mCRPC was 30.39 months in the good nutritional status group and 11.07 months in the poor nutritional status group (<jats:italic>p</jats:italic> of log rank &lt;0.001). In a multivariate model, poor nutritional status was an independent risk factor in overall survival (Hazard Ratio [HR] = 5.37, 95% Confidence Interval [CI] 3.27–8.83), together with a high metastatic volume (HR = 4.03, 95% CI 2.16–7.53) and docetaxel cumulative dosage (HR = 0.999, 95% CI 0.999–0.9998).</jats:p><jats:p><jats:bold>Conclusion:</jats:bold> Poor nutritional status with a GNRI &lt;92 is associated with shorter progression free survival and overall survival in mCRPC patients treated with docetaxel. Metastatic volume and cumulative docetaxel dosage are also independent prognostic factors in overall survival.</jats:p>
SDGs

[SDGs]SDG2

[SDGs]SDG3

Publisher
Frontiers Media SA
Type
journal-article
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback